Lineage Cell Therapeutics, Inc.
LCTX
$1.11
$0.032.78%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 1.48M | -4.81M | 851.00K | -29.78M | -30.46M |
| Total Depreciation and Amortization | 187.00K | 188.00K | 186.00K | 178.00K | 171.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -8.55M | -1.34M | -6.00M | 27.56M | 27.11M |
| Change in Net Operating Assets | -366.00K | -2.12M | 83.00K | -1.57M | -2.35M |
| Cash from Operations | -7.24M | -8.08M | -4.88M | -3.62M | -5.54M |
| Capital Expenditure | -108.00K | -55.00K | -399.00K | -12.00K | -14.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.07M | -2.27M | -14.94M | 0.00 | 0.00 |
| Cash from Investing | 3.96M | -2.33M | -15.33M | -12.00K | -14.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9.00K | -14.00K | -15.00K | -16.00K | -14.00K |
| Issuance of Common Stock | 4.48M | 5.62M | 20.40M | 2.08M | -- |
| Repurchase of Common Stock | 0.00 | -40.00K | -1.00K | 0.00 | -65.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | -232.00K | -228.00K |
| Cash from Financing | 4.47M | 5.56M | 20.38M | 1.83M | -307.00K |
| Foreign Exchange rate Adjustments | 259.00K | -5.00K | 180.00K | -4.00K | 293.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.44M | -4.85M | 347.00K | -1.80M | -5.57M |